Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1)

被引:24
|
作者
Thomas, J. -A., II [1 ,2 ]
Gerber, L. [1 ,2 ]
Moreira, D. M. [3 ]
Hamilton, R. J. [4 ]
Banez, L. L. [1 ,2 ]
Castro-Santamaria, R. [5 ]
Andriole, G. L. [6 ]
Isaacs, W. B. [7 ]
Xu, J. [8 ]
Freedland, S. J. [1 ,2 ,9 ]
机构
[1] Duke Univ, Sch Med, Dept Surg, Duke Prostate Ctr,Div Urol Surg, Durham, NC 27710 USA
[2] Durham VA Med Ctr, Surg Sect, Durham, NC USA
[3] Author Smith Inst Urol, New Hyde Pk, NY USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] Washington Univ, Sch Med St Louis, St Louis, MO USA
[7] Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA
[8] Wake Forest Univ, Ctr Genom & Personalized Med Res, Winston Salem, NC 27109 USA
[9] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA
关键词
breast cancer; family history; prostate cancer; REDUCE; RELATIVES; METAANALYSIS; MUTATIONS; PROBANDS; ANTIGEN; CANADA; SWEDEN; COHORT;
D O I
10.1111/j.1365-2796.2011.02504.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
. Thomas J-A II, Gerber L, Moreira DM, Hamilton RJ, Banez LL, Castro-Santamaria R, Andriole GL, Isaacs WB, Xu J, Freedland SJ (Durham VA Medical Center, Durham, NC, USA; Duke University School of Medicine, Durham, NC, USA; The Author Smith Institute for Urology, New Hyde Park, NY, USA; Memorial Sloan-Kettering Cancer Center, New York, NY, USA; GlaxoSmithKline, Research Triangle Park, NC, USA; Washington University School of Medicine, St. Louis, MO, USA; Johns Hopkins Hospital, Baltimore, MD, USA; Wake Forest University, Winston-Salem, NC, USA; and Duke University School of Medicine, Durham, NC, USA). Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med 2012; 272: 8592. Background. To what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast cancer (BCa) are attributable to screening biases is unclear. We examined these questions within the REDUCE study, where biopsies were largely independent of prostate specific antigen (PSA) minimizing screening biases. Methods. Data were from REDUCE, which tested dutasteride 0.5 mg daily for PCa risk reduction in men with PSA 2.510.0 ng mL-1 and a negative prestudy biopsy. Among men undergoing at least one on-study biopsy with complete data (n = 6415; 78.1%), the association between family history and PCa risk was tested using multivariate logistic regression adjusting for clinicodemographic characteristics. Results. A family history of PCa alone was associated with increased PCa diagnosis (OR: 1.47, 95%CI: 1.221.77). In North America, PCa family history was not related to PCa diagnosis (OR: 1.02, 95%CI: 0.731.44), whereas outside North America, PCa family history was significantly related to diagnosis (OR: 1.72, 95%CI: 1.382.15) (P-interaction = 0.01). A family history of both PCa and BCa (OR: 2.54, 95%CI: 1.723.75) but not BCa alone (OR: 1.04, 95%CI: 0.841.29) was associated with increased PCa risk versus no family history and irrespective of geographical region. Conclusions. In REDUCE, PCa family history was significantly related to PCa diagnosis, although only for men outside North America. The presence of both PCa and BCa family history significantly increased risk versus PCa family history alone, irrespective of geographical region. Ultimately, our observations may support the need for changes in how we address family history in terms of both risk of PCa diagnosis and general risk stratification.
引用
收藏
页码:85 / 92
页数:8
相关论文
共 50 条
  • [41] Re: Baseline Prostate Inflammation is Associated with a Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy: Results from the REDUCE Study Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2014, 192 (01): : 128 - 128
  • [42] Occupation and prostate Cancer risk: results from the epidemiological study of prostate cancer (EPICAP)
    Bijoux, Wendy
    Cordina-Duverger, Emilie
    Balbolia, Soumaya
    Lamy, Pierre-Jean
    Rebillard, Xavier
    Tretarre, Brigitte
    Cenee, Sylvie
    Menegaux, Florence
    JOURNAL OF OCCUPATIONAL MEDICINE AND TOXICOLOGY, 2022, 17 (01)
  • [43] Family history of breast cancer as a predictor for fatal prostate cancer
    Rodríguez, C
    Calle, EE
    Tatham, LM
    Wingo, PA
    Miracle-McMahill, HL
    Thun, MJ
    Heath, CW
    EPIDEMIOLOGY, 1998, 9 (05) : 525 - 529
  • [44] FAMILY HISTORY AND THE RISK OF PROSTATE-CANCER
    STEINBERG, GD
    CARTER, BS
    BEATY, TH
    CHILDS, B
    WALSH, PC
    PROSTATE, 1990, 17 (04): : 337 - 347
  • [45] Family history and risk of fatal prostate cancer
    Rodriguez, C
    Calle, EE
    MiracleMcMahill, HL
    Tatham, LM
    Wingo, PA
    Thun, MJ
    Heath, CW
    EPIDEMIOLOGY, 1997, 8 (06) : 653 - 657
  • [46] FAMILY HISTORY AND RISK OF PROSTATE-CANCER
    LESKO, SM
    ROSENBERG, L
    SHAPIRO, S
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 141 (11) : S27 - S27
  • [47] Risk of prostate cancer mortality in men with a history of prior cancer
    Dinh, Kathryn T.
    Mahal, Brandon A.
    Ziehr, David R.
    Muralidhar, Vinayak
    Chen, Yu-Wei
    Viswanathan, Vidya B.
    Nezolosky, Michelle D.
    Beard, Clair J.
    Choueiri, Toni K.
    Martin, Neil E.
    Orio, Peter F.
    Sweeney, Christopher J.
    Quoc-Dien Trinh
    Nguyen, Paul L.
    BJU INTERNATIONAL, 2016, 117 (6B) : E20 - E28
  • [48] Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer (LPC).
    Albright, Frederick S.
    Agarwal, Neeraj
    Lowrance, William Thomas
    Stephenson, Robert A.
    Alex, Anitha
    Cannon-Albright, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [49] Risk of prostate cancer and family history of cancer: a population based study in China
    Bai, Y
    Gao, YT
    Deng, J
    Sesterhenn, IA
    Fraumeni, JF
    Hsing, AW
    PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (01) : 60 - 65
  • [50] Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer
    Brandt, A.
    Sundquist, J.
    Hemminki, K.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 251 - U98